Poor
Mostly Misaligned
Patient Risk:
Moderate
Summary
Several safety-related claims are not supported by the provided label text (e.g., diabetes risk, hepatitis, pancreatitis, and hydration preventing kidney damage). One claim includes an outcome ('even death') that is not explicitly supported in the provided label citations. Some safety statements are overstated beyond labeled phrasing (e.g., 'common side effects' and broad 'kidney damage' framing).
Category Scores
Accurate Statements
Lipitor is also known as atorvastatin.
11 DESCRIPTION (atorvastatin is the active ingredient in LIPITOR).
Generic atorvastatin is available in various strengths including 10 mg, 20 mg, 40 mg, and 80 mg.
11 DESCRIPTION and 3 DOSAGE FORMS AND STRENGTHS (LIPITOR tablets contain 10, 20, 40, and 80 mg atorvastatin).
A rare but serious side effect of atorvastatin is rhabdomyolysis, in which muscle tissue breaks down.
5.1 Skeletal Muscle (rare cases of rhabdomyolysis); 6 ADVERSE REACTIONS (rhabdomyolysis and myopathy).
Pregnant women should avoid atorvastatin.
4.3 Pregnancy (LIPITOR may cause fetal harm; discontinue if pregnancy occurs).
Breastfeeding women should avoid atorvastatin.
4.4 Nursing mothers (women who require LIPITOR should not breastfeed).
Atorvastatin can harm the fetus or baby.
4.3 Pregnancy (may cause fetal harm); 4.4 Nursing mothers (potential for serious adverse reactions in nursing infants).
Regular liver function tests can help identify potential liver damage caused by atorvastatin.
5.2 Liver Dysfunction (recommended LFTs prior to and at 12 weeks after initiation and after dose elevations; periodically thereafter); 17.2 Liver Enzymes.
Muscle pain or weakness while taking atorvastatin should be reported to a doctor immediately.
5.1 Skeletal Muscle (patients should report promptly unexplained muscle pain/tenderness/weakness); 17.1 Muscle Pain.
Unsupported Statements
Generic atorvastatin contains the same active ingredient as Lipitor but is manufactured by different companies.
No manufacturer/“generic” equivalence statement is present in the provided label text.
Common side effects of atorvastatin include muscle pain, weakness, and tenderness.
The label advises reporting unexplained muscle pain/tenderness/weakness; it does not label these as 'common side effects' in the provided excerpts.
Atorvastatin can cause liver damage, including elevated liver enzymes and liver failure.
Elevated liver enzymes/biochemical liver function abnormalities are supported, but 'liver failure' is not explicitly supported in the provided label sections.
Atorvastatin may increase the risk of developing diabetes.
No diabetes-risk statement is present in the provided label text.
Atorvastatin can cause kidney damage, including kidney failure.
The label provided links rhabdomyolysis with acute renal failure secondary to myoglobinuria, but it does not broadly state 'kidney damage' or 'kidney failure' as general complications attributable to atorvastatin.
Rhabdomyolysis caused by atorvastatin can lead to kidney damage and even death.
Acute renal failure secondary to rhabdomyolysis is supported, but 'even death' is not explicitly supported in the provided label excerpts.
Atorvastatin can cause hepatitis.
No hepatitis statement is present in the provided label text.
Atorvastatin may increase the risk of pancreatitis.
No pancreatitis-risk statement is present in the provided label text.
People with kidney disease should avoid atorvastatin because it can worsen kidney function.
The provided label excerpt states renal impairment is a risk factor for rhabdomyolysis with acute renal failure; it does not explicitly state that atorvastatin 'worsens kidney function' as a basis to avoid therapy.
Drinking plenty of water can help prevent kidney damage caused by atorvastatin.
No hydration/fluids preventive instruction for kidney damage is present in the provided label text.
Contradictions
Low
AI Statement
Rhabdomyolysis caused by atorvastatin can lead to kidney damage and even death.
Label Reference
5.1 Skeletal Muscle (rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria); 6 ADVERSE REACTIONS (rhabdomyolysis and myopathy).
Important Omissions
Contraindications beyond pregnancy/nursing are not assessed (e.g., active liver disease/unexplained persistent transaminase elevations).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple claims are either unsupported or overstated (e.g., diabetes risk, hepatitis, pancreatitis, hydration preventing kidney damage). One claim adds an outcome ('even death') not explicitly supported in the provided excerpts, which could mislead about severity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Misaligned
Primary Issue
Several adverse-effect and prevention claims are not supported by the provided label sections, and one claim includes 'even death' not explicitly supported in the cited label text.
Suggested Improvement
Limit safety claims to what is explicitly supported in the provided label excerpts (e.g., rhabdomyolysis with acute renal failure; liver enzyme abnormalities and recommended monitoring) and remove or rephrase unsupported items (diabetes, hepatitis, pancreatitis, hydration prevention, and 'even death').